A Phase 2/3 interventional study of PF-07275315 dose 1 and PF-07275315-dose 2 in Moderate to Severe Chronic Obstructive Pulmonary Disease, sponsored by Pfizer. Recruiting at 189 sites in 18 countries. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment
Australia, Bulgaria, France, Germany, Italy, Poland, Spain, United Kingdom
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Pulmonary Disease, Chronic Obstructive by Pfizer — 2 open to participants now, 2 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Pfizer.
Among the 22 studies in Pulmonary Disease, Chronic Obstructive by Pfizer, this one is the 2nd largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2026, is the only one in phase 2/3, and was the 21st registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 22 studies in Pulmonary Disease, Chronic Obstructive by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
By country, each count listing its studies:
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 35 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 3
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,156 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 105 across the 19 interventional studies, 57 across the 3 observational. Of the 19 that completed or were terminated, 5 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Pulmonary Disease, Chronic Obstructive by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breathe, which negatively impacts the quality of life and functioning of people who are affected.
This study is seeking participants who:
All participants will receive PF-07275315 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied.
PF-07275315 or placebo will be given as multiple shots in the clinic over the course of 24 weeks for the Phase 2 part and 52 weeks for the Phase 3 part. We will compare the results of people receiving PF-07275315 to those of the people who do not. This will help us determine if PF-07275315 is safe and effective.
Participants who will be involved in the Phase 2 part of the study for about 40 weeks. During this time, they will have 11 visits at the study clinic.
Participants who will be involved in the Phase 3 part of the study for about 68 weeks. During this time, they will have 18 visits at the study clinic.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PF-07275315-dose 3
Drug: PF-07275315-dose 2
Drug: PF-07275315 dose 1
Drug: Placebo
Drug: Placebo
SC injection dose 1
SC injection dose 2
SC injection matched
SC injection dose 3
Phase 2 part: Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 24
FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FEV1 is obtained from spirometry.
Time frame: Baseline to Week 24
Phase 3 part: Annualized rate of moderate or severe ECOPD
Exacerbation of Chronic Obstructive Pulmonary Disease (ECOPD) are sudden worsening of respiratory symptoms that significantly worsen lung function and quality of life.
Time frame: Baseline to Week 52
Phase 2: Annualized rate of moderate or severe ECOPD.
Time frame: Baseline to Week 24
Phase 2: Change from baseline in pre-BD FEV1 up to Week 24.
Time frame: Baseline to Week 24
Phase 2: Change from baseline in trough, pre- and post-BD FEV1 up to Week 24
Time frame: Baseline to Week 24
Phase 2: Change from baseline in trough, pre- and post-BD FVC and FEV1/FVC ratio, % predicted FEV1, % predicted FVC up to Week 24.
Time frame: Baseline to Week 24
Phase 2: Change from baseline in trough FEV1 responsiveness to BD up to Week 24.
Time frame: Baseline to Week 24
Phase 2: Incidence and severity of TEAEs throughout Phase 2 part of the study.
Time frame: Baseline to Week 24
Phase 2: Incidence of treatment-emergent adverse events and serious adverse events leading to discontinuation.
Time frame: Baseline to Week 24
Phase 2: Incidence of clinical abnormalities in clinical laboratory values, ECG measurements, and vital signs.
Time frame: Baseline to Week 24
Phase 3: change from baseline in pre- and post-BD FEV1 at Week 12 and Week 52.
Time frame: Baseline to Week 52
Phase 3: Percentage of participants with ≥4 points improvement from baseline in Saint George's Respiratory Questionnaire (SGRQ) score at Week 52.
Time frame: Baseline to Week 52
Phase 3: Percentage of participants with ≥2 points improvement from baseline in the COPD Assessment Test (CAT) total score at Week 52.
Time frame: Baseline to Week 52
Phase 3: Percentage of participants with ≥2 points improvement from baseline in E-RS:COPD total score at Week 52.
Time frame: Baseline to Week 52
Phase 3: Annualized rate of severe ECOPD.
Time frame: Baseline to Week 52
Phase 2: Change from baseline of clinical abnormalities in clinical laboratory values, ECG measurements, and vital signs.
Time frame: Baseline to Week 24
Phase 3: Annualized rate of exacerbations requiring emergency department visit and/or hospitalization.
Time frame: Baseline to Week 52
Showing the first 100 of 189 sites across 18 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Started Feb 2026 (actual). Primary completion is estimated for Oct 2030, 56 months after the start.
How these figures are worked out, and which studies are left out of them.
Australia, Bulgaria, France, Germany, Italy, Poland, Spain, United Kingdom
Australia, Bulgaria, France, Germany, Italy, Poland, Spain, United Kingdom
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tilrekimig
Pulmonary Disease, Chronic Obstructive →